Beam Therapeutics vs Karyopharm Therapeutics
Beam Therapeutics and Karyopharm Therapeutics are similar in size: $140m and $146m of revenue in their latest fiscal years. Beam Therapeutics grew faster (120.0% against 0.6%). Beam Therapeutics kept more of each dollar of sales as profit: a net margin of -57.2% against -134.2%.
| Latest fiscal year | Beam TherapeuticsBEAM, 2025 | Karyopharm TherapeuticsKPTI, 2025 |
|---|---|---|
| Revenue | $140m | $146m |
| Revenue growth | 120.0% | 0.6% |
| Net income | −$80.0m | −$196m |
| Operating margin | -274.6% | -62.1% |
| Net margin | -57.2% | -134.2% |
| Return on equity | -8.1% | — |
| Free cash flow | −$360m | −$75.4m |
| Cash | $295m | $60.5m |
| Total debt | $0 | $94.8m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 511 | 228 |
| Market value | $2.74bn | $2.0m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 31 sales | 0 buys, 21 sales |